Table 3 Drug efficacy in PDX models and OncoVee^® MiniPDX capsules in mice

GAYW5

Stomach

Poor/moderately differentiated AC, 80%

S-1 (1)

95 ± 6

+

94 ± 15

+

GAYW7

Stomach

Poorly differentiated AC, 90%

S-1 (1)

86 ± 10

+

92 ± 3

+

GAYL1

Stomach

Mucinous AC, 80%

S-1 (1)

37 ± 10

–

13 ± 29

–

GAYB7

Stomach

Poorly differentiated tubular AC, 70%

S-1 (1)

44 ± 16

–

14 ± 20

–

GAYP53

Stomach

Poor-moderately differentiated AC, 90%

S-1 (1)

35 ± 10

–

17 ± 13

–

GASIL2

Stomach

Moderately differentiated AC, 40%

S-1 + Oxaliplatin (2)

29 ± 20

–

40 ± 17

–

GABSI3

Stomach

Poorly differentiated AC, 80%

S-1 + Oxaliplatin (2)

37 ± 12

–

75 ± 4

+

GAYP93

Stomach

Moderately differentiated AC, 90%

S-1 + Oxaliplatin(2)

27 ± 20

–

29 ± 15

–

GAYP97

Stomach

Moderately differentiated AC, 90%

S-1 + Oxaliplatin (2)

7 ± 29

–

9 ± 10

–

GAJ07

Stomach

Poor-moderately differentiated AC, 50%

Capecitabine + Oxaliplatin (3)

80 ± 3

+

35 ± 13

–

GASI80

Stomach

Poorly differentiated AC, 80%

Capecitabine + Oxaliplatin (3)

112 ± 3

+

50 ± 11

+

GASI05

Stomach

Moderately differentiated AC, 40%

Epirubicin + Capecitabine + Oxaliplatin (4)

97 ± 16

+

45 ± 23

+

GASAB3

Stomach

Poorly differentiated AC, 90%

Cisplatin + 5-FU + Docetaxel (5)

43 ± 17

–

17 ± 14

–

GAYP16

Stomach

Poorly differentiated AC, 90%

Cisplatin + 5-FU + Docetaxel (5)

32 ± 16

–

−13 ± 39

–

GAYP53

Stomach

Poor-moderately differentiated AC, 90%

Cisplatin + 5-FU + Docetaxel (5)

125 ± 3

+

50 ± 7

+

LULI02

Lung

Poorly differentiated SCC, 98%

Docetaxel (6)

97 ± 12

+

51 ± 7

+

LULI03

Lung

Poorly differentiated AC, 98%

Docetaxel (6)

12 ± 23

–

15 ± 10

–

LULI20

Lung

Poorly differentiated AC, 98%

Docetaxel (6)

91 ± 14

+

86 ± 3

+

LULI21

Lung

Poorly differentiated SCC, 78%

Docetaxel (6)

42 ± 16

–

−61 ± 29

–

LULI27

Lung

Moderate-highly differentiated SCC, 80%

Docetaxel (6)

115 ± 3

+

32 ± 11

–

LULI55

Lung

Large cell carcinoma, 95%

Docetaxel (6)

109 ± 1

+

14 ± 4

–

CTYW012

Lung

Poor-moderately differentiated AC, 90%

Gemzar + Cisplatin (7)

116 ± 0

+

84 ± 7

+

LULI49

Lung

Poorly differentiated AC, 90%

Erlotinib (8)

40 ± 15

–

−16 ± 26

–

CTC15063

Lung

Poor-moderately differentiated AC, 95%

Erlotinib (8)

37 ± 19

–

21 ± 17

–

CTC15063

Lung

Poor-moderately differentiated AC, 95%

AZD9291 (9)

167 ± 5

+

61 ± 3

+

CTC16075

Lung

Poorly differentiated carcinoma, 90%

Crizotinib (10)

103 ± 2

+

102 ± 4

+

PAYY8

Pancreas

Poorly differentiated ductal AC, 90%

Gemzar (11)

27 ± 27

–

−14 ± 10

–

PAYY5

Pancreas

Poor-moderately differentiated ductal AC, 80%

Gemzar (11)

75 ± 9

+

56 ± 8

+

PAYY5

Pancreas

Poor-moderately differentiated ductal AC, 80%

Oxaliplatin + Irinotecan (12)

112 ± 2

+

54 ± 6

+